title: Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients.
abstract: BACKGROUND
  Psoriasis is immune-mediated chronic inflammatory disease with preference for skin and joints. The skin involvement occurs by hyperproliferation and abnormal differentiation of keratinocytes. It is associated with comorbidities, mainly related to the clinical manifestations of the metabolic syndrome. Increased TNF-alpha expression (TNF-α) is related to its pathophysiology. Infliximab is an intravenous drug that acts neutralizing the biological activity of TNF-α and prevents the binding of the molecule to the target cell receptor, inhibiting cell proliferation of psoriasis and other diseases mediated by TNF-α. A lot of infusion reactions have been described in the literature.
  
  
  OBJECTIVE
  To evaluate the adverse effects of intravenous treatment with infliximab, analyzing patients with psoriasis compared to those with other chronic inflammatory diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis).
  
  
  METHODS
  Analysis of medical records and adverse events of 168 patients undergoing infliximab infusion for psoriasis and chronic inflammatory diseases treatment.
  
  
  RESULTS
  168 patients who have used infliximab were evaluated, 24 had psoriasis and 144 had chronic inflammatory diseases. Only 2 (8.3%) patients with psoriasis showed adverse events requiring treatment discontinuation, and just 6 (4.2%) female patients with chronic inflammatory diseases experienced adverse events.
  
  
  CONCLUSIONS
  Infliximab is a safe drug, with a low percentage of adverse events and there were more adverse events in women with chronic inflammatory diseases and in patients who received more infliximab infusions.
authors.affiliation: Faculdade Estadual de Medicina de São José do Rio Preto (FAMERP) - São José do Rio Preto (SP), Brazil.|Hospital de Base de São José do Rio Preto - São José do Rio Preto (SP), Brazil.
authors.forename: João Roberto
authors.initials: JR
authors.lastname: Antonio
authors.affiliation: Faculdade Estadual de Medicina de São José do Rio Preto (FAMERP) - São José do Rio Preto (SP), Brazil.
authors.forename: Jessica
authors.initials: J
authors.lastname: Sanmiguel
authors.affiliation: Faculdade Estadual de Medicina de São José do Rio Preto (FAMERP) - São José do Rio Preto (SP), Brazil.
authors.forename: Giovana Viotto
authors.initials: GV
authors.lastname: Cagnon
authors.affiliation: Faculdade Estadual de Medicina de São José do Rio Preto (FAMERP) - São José do Rio Preto (SP), Brazil.
authors.forename: Marília Silveira Faeda
authors.initials: MS
authors.lastname: Augusto
authors.affiliation: Faculdade Estadual de Medicina de São José do Rio Preto (FAMERP) - São José do Rio Preto (SP), Brazil.
authors.forename: Moacir Fernandes de
authors.initials: MF
authors.lastname: Godoy
authors.affiliation: Faculdade Estadual de Medicina de São José do Rio Preto (FAMERP) - São José do Rio Preto (SP), Brazil.
authors.forename: Eurides Maria Oliveira
authors.initials: EM
authors.lastname: Pozetti
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012189:Retrospective Studies; D012737:Sex Factors; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab